Provided by Tiger Trade Technology Pte. Ltd.

Incyte

112.75
-0.6900-0.61%
Post-market: 112.750.00000.00%16:17 EDT
Volume:1.93M
Turnover:216.34M
Market Cap:22.85B
PE:14.36
High:113.75
Open:112.89
Low:110.08
Close:113.44
52wk High:132.60
52wk Low:82.82
Shares:202.70M
Float Shares:169.82M
Volume Ratio:0.94
T/O Rate:1.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):7.85
EPS(LYR):6.41
ROE:30.67%
ROA:16.83%
PB:3.60
PE(LYR):17.59

Loading ...

Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM), Immunome (IMNM) and Incyte (INCY)

TIPRANKS
·
Jul 22

Incyte: ENHANZE Licensing Bolsters INCA033989 Outlook as Buy Rating and $140 Price Target Are Reiterated

TIPRANKS
·
Jul 22

Incyte Price Target Maintained with a $140.00/share by HC Wainwright & Co.

Dow Jones
·
Jul 21

Halozyme Therapeutics (HALO) Lands Incyte Deal On A Valuation That Still Looks Undervalued

Simply Wall St.
·
Jul 21

Earning Preview: Incyte Q2 revenue is expected to increase by 24.52%, and institutional views are bullish

Earnings Agent
·
Jul 21

Top Incyte Executives Quietly Lock In Profits With Fresh Stock Sales

TIPRANKS
·
Jul 21

Incyte Corp. Stock Underperforms Monday When Compared to Competitors

Dow Jones
·
Jul 21

Incyte EVP, Head of U.S. Commercial Issa Mohamed Khairie Sells 1,093 Shares for $125,705.93

Reuters
·
Jul 21

Halozyme Therapeutics, Incyte Sign Deal to Develop Subcutaneous Formulations of Blood Cancer Drug

MT Newswires Live
·
Jul 20

Goldman Sachs Adjusts Price Target on Incyte to $110 From $100, Maintains Neutral Rating

MT Newswires Live
·
Jul 20

Halozyme announces global collaboration, license agreement with Incyte

TIPRANKS
·
Jul 20

Halozyme Partners with Incyte on Enhanze Subcutaneous Formulation for Inca033989 Antibody

Reuters
·
Jul 20

Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of Inca033989 Using Its Enhanze® Technology

THOMSON REUTERS
·
Jul 20

Halozyme Therapeutics - Eligible to Receive Royalties on Net Sales of Enhanze Medicines

THOMSON REUTERS
·
Jul 20

Halozyme Therapeutics - to Receive Upfront Payment and Eligible for Milestone Payments from Incyte

THOMSON REUTERS
·
Jul 20

Halozyme Therapeutics - Incyte Granted Rights to Develop Enhanze with Mutcalr Program and Option for Two Additional Targets

THOMSON REUTERS
·
Jul 20

Incyte (INCY) Reports Promising Latarcibart Data As Global Phase 3 Begins

Simply Wall St.
·
Jul 17

Incyte Corp. Stock Underperforms Thursday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Jul 17

Incyte CMO Steven H. Stein Disposes of 53,155 Shares Worth $6.05 Million

Reuters
·
Jul 17

BofA Securities Raises Incyte Price Target to $136 From $124

MT Newswires Live
·
Jul 15